|
Orthologous residues
|
|
CSF2RB (human): S601‑p, CSF2RB (mouse): S603‑p, CSF2RB iso2 (mouse): S603‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
CTL-EN (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (mouse)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin
|
|
|
|
increase
|
|
|
cAMP analog
|
|
|
|
increase
|
|
|
IL-3
|
|
|
|
increase
|
|
|
H-89
|
IL-3
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
apoptosis, inhibited
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
PIK3R1 (mouse)
|
|
Induces
|
|
apoptosis, altered
|
|
|
14-3-3 beta (mouse)
|
|
Induces
|
|
apoptosis, altered
|
|
|
